Trial Profile

An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecaprevir/pibrentasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Acronyms MAGELLAN-3
Sponsors AbbVie; AbbVie Germany

15 Nov 2021 Results (n=32) assessing efficacy and safety of retreatment of patients who failed glecaprevir/pibrentasvir, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
11 Aug 2021 Status changed from active, no longer recruiting to completed.
28 Oct 2020 Planned End Date changed from 2 Jun 2021 to 29 Jul 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com